3.6801

11.36% -0.3999

Tango Therapeutics Inc (TNGX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TNGX Giù? Forum Previsione

Precedente Chiudi:

$4.08

Aprire:

$4.07

Volume 24 ore:

2.31M

Relative Volume:

1.31

Capitalizzazione di mercato:

$394.22M

Reddito:

$42.51M

Utile/perdita netta:

$-116.49M

Rapporto P/E:

-3.0414

EPS:

-1.21

Flusso di cassa netto:

$-120.82M

1 W Prestazione:

-7.74%

1M Prestazione:

-49.42%

6M Prestazione:

-51.59%

1 anno Prestazione:

-51.39%

Intervallo 1D:

$3.58

$4.22

Intervallo di 1 settimana:

$3.54

$4.22

Portata 52W:

$2.70

$13.01

Tango Therapeutics Inc Stock (TNGX) Company Profile

Nome

Tango Therapeutics Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

(857) 320-4900

Indirizzo

201 BROOKLINE AVENUE, BOSTON

Dipendente

140

Cinguettio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

TNGX's Discussions on Twitter

Confronta TNGX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TNGX	3.685	394.22M	42.51M	-116.49M	-120.82M	-1.21
VRTX	449.84	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	745.43	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	590.99	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	245.91	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	107.45	24.89B	3.30B	-501.07M	1.03B	11.54

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-08	Iniziato	B. Riley Securities	Buy
2022-10-20	Aggiornamento	H.C. Wainwright	Neutral → Buy
2021-09-20	Iniziato	SVB Leerink	Outperform

Tango Therapeutics Inc Borsa (TNGX) Ultime notizie

Nov 19, 2024

Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 18, 2024

Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com

Nov 18, 2024

Nov 17, 2024

Trv Gp Iv LLC Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat

Nov 17, 2024

Nov 15, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Nov 15, 2024

B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World

Nov 15, 2024

Nov 14, 2024

B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat

Nov 14, 2024

B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00 - Defense World

Nov 14, 2024

Nov 13, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 inhibitor progress - Investing.com

Nov 13, 2024

Nov 12, 2024

Tango Therapeutics (NASDAQ:TNGX) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 12, 2024

Nov 11, 2024

The Analyst Landscape: 5 Takes On Tango Therapeutics - Benzinga

Nov 11, 2024

B. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat

Nov 11, 2024

FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World

Nov 11, 2024

Leerink Partnrs Brokers Increase Earnings Estimates for TNGX - MarketBeat

Nov 11, 2024

Nov 09, 2024

EcoR1 Capital sells $8.4 million in Tango Therapeutics stock - Investing.com India

Nov 09, 2024

EcoR1 Capital sells $8.4 million in Tango Therapeutics stock By Investing.com - Investing.com Australia

Nov 09, 2024

Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024

Tango Therapeutics sees $9.67m stock sale by Boxer Capital - Investing.com India

Nov 07, 2024

Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim - MarketBeat

Nov 07, 2024

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Nov 07, 2024

Nov 06, 2024

Two to Tango: Brain cancer drugs go further into development - BioWorld Online

Nov 06, 2024

Tango stock plunges 28% amid pipeline updates, Q3 earnings report (NASDAQ:TNGX) - Seeking Alpha

Nov 06, 2024

U.S. Stock market: Sunnova energy(-42.35%0, Zoomcar(-38.48%), Tango therapeutics(-27.22%) among stock losers during early trading - Business Upturn

Nov 06, 2024

Tango Shares Plunge After 3Q Loss, Product Plans - MarketWatch

Nov 06, 2024

Tango Therapeutics advances cancer drug into full development By Investing.com - Investing.com Canada

Nov 06, 2024